Luminex Receives FDA Emergency Use Authorization and CE Mark for Expanded NxTAG(R) Respiratory Panel Test Including SARS-CoV-2

Provides labs with high throughput, syndromic respiratory testing capabilities AUSTIN, Texas, March 4, 2021 -- (Healthcare Sales & Marketing Network) -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received Emergency Use Authorization... Diagnostics, FDA, Regulatory Luminex, SARS-CoV-2, COVID-19, NxTAG
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news